Michael Chiu

Michael Chiu is the CEO of Kytopen, a Cambridge, Massachusetts biotech spun out of an MIT lab that builds the Flowfect platform - a non-viral, continuous-flow way to shuttle DNA, mRNA and CRISPR payloads into living cells at manufacturing scale. A mechanical engineer with a PhD and MBA from MIT, Chiu has spent his career turning laboratory hardware into shipped products, founding and selling companies in energy harvesting, healthcare, and bioprocessing before taking Kytopen's helm in August 2023 to push cell therapy manufacturing out of the bottleneck.